Rachna T. Shroff, MD, MS, FASCO

Rachna Shroff, MD, MS, FASCO, is interim clinical affairs director, associate director of Clinical Investigations, and co-lead of Gastrointestinal Clinical Research Team at The University of Arizona Cancer Center. She is also a professor in the Department of Medicine, chief of the Division of Hematology/Oncology, medical director of the Oncology Service Line, and associate dean of Clinical and Translational Research at The University of Arizona College of Medicine.

Articles

Optimal Sequencing in Patients With Advanced HCC

August 3rd 2023

Key opinion leaders discuss the sequencing of systemic therapy options for patients with advanced HCC.

Updates in First-Line Systemic Therapy for Advanced HCC: The HIMALAYA Study

August 3rd 2023

Dr Manish Shah reviews data from the HIMALAYA study on front-line systemic therapy in advanced HCC with tremelimumab plus durvalumab.

Updates in First-Line Systemic Therapy for Advanced HCC: The IMbrave150 Trial

July 28th 2023

Julio Gutierrez, MD, and Ghassan K. Abou-Alfa, MD, discuss the results of the IMbrave150 study investigating atezolizumab plus bevacizumab in the first-line setting for advanced HCC.

The Role of Adjuvant Therapy in Patients With Early-Stage HCC

July 28th 2023

Experts review data from IMbrave050 on the potential role of atezolizumab plus bevacizumab in the adjuvant setting for HCC.

Treatment Approaches for Patients With Early-Stage HCC

July 19th 2023

Manish Shah, MD, details the role of locoregional therapy in HCC, and Julio Gutierrez, MD, comments on transplant as a curative option.

Factoring Stage and Hepatic Function Into Treatment Decision-Making for HCC

July 19th 2023

The panel explains the Child-Pugh scoring system and how staging and liver function impact treatment decisions for patients with HCC.

Diagnosing Patients With Hepatocellular Carcinoma

July 12th 2023

Key opinion leaders review the process of diagnosing HCC, the role of molecular testing, and associated challenges.

Overview of Hepatocellular Carcinoma (HCC)

July 12th 2023

Experts provide an overview of hepatocellular carcinoma, including the risk factors and prognosis.

The Evolving Treatment Landscape of Biliary Tract Cancers

March 22nd 2023

Closing out their discussion on biliary tract cancers, expert panelists share key takeaways and excitement for the evolving treatment paradigm.

Novel Targeted Therapies Under Investigation in Biliary Tract Cancers

March 22nd 2023

Comprehensive insight on novel targeted agents under investigation in the setting of biliary tract cancers.

TOPAZ-1: Chemotherapy + Durvalumab in Biliary Tract Cancers

March 15th 2023

Centering discussion on the TOPAZ-1 trial of chemotherapy in combination with durvalumab, panelists consider how this regimen has impacted clinical practice.

Standard of Care Systemic Therapies for Biliary Tract Cancers

March 8th 2023

Key opinion leaders in the field of biliary tract cancers highlight mainstay systemic therapy regimens within the treatment paradigm.

Role for Liver Transplant in Biliary Tract Cancers

March 8th 2023

A brief discussion on the continued role of liver transplant in biliary tract cancers and when it is appropriate to consider a patient for this procedure.

Liver-Directed Treatment Strategies in Biliary Tract Cancers

March 1st 2023

A comprehensive review of liver-directed therapies available to aid in the management of biliary tract cancers.

Biliary Tract Cancers: Surgical and Perioperative Treatment Strategies

March 1st 2023

Moving on to identify specific treatment modalities, panelists discuss the surgical and perioperative strategies used to manage biliary tract cancers.

Advent of Molecular Testing in Biliary Tract Cancers

February 22nd 2023

Key opinion leaders review the advent of molecular testing in biliary tract cancers and consider its impact on informing treatment decisionmaking.

Optimizing the Staging of Biliary Tract Cancers

February 22nd 2023

Focused conversation on the optimal workup and staging of biliary tract cancers within the current paradigm.

Clinical Scenario: Diagnostic Strategies to Identify Biliary Tract Cancers

February 15th 2023

Centering focus on a patient scenario, panelists break down mainstay diagnostic strategies used to identify biliary tract cancers.

Overview on Biliary Tract Cancers and Their Rising Incidence

February 15th 2023

Expert panelists open their discussion on biliary tract cancers by identifying various subsets and noting the growing incidence of these diseases.

Dr. Shroff on Results of the SWOG 1815 Trial in Advanced Biliary Tract Cancers

January 20th 2023

Rachna T. Shroff, MD, MS, discusses efficacy data from the phase 3 SWOG 1815 trial investigating nab-paclitaxel plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in newly diagnosed patients with advanced biliary tract cancers.